INT1734

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.57
First Reported 1979
Last Reported 2010
Negated 1
Speculated 1
Reported most in Abstract
Documents 116
Total Number 117
Disease Relevance 125.13
Pain Relevance 10.52

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

small molecule metabolic process (HSD11B1) oxidoreductase activity (HSD11B1) endoplasmic reticulum (HSD11B1)
Anatomy Link Frequency
blood 4
plasma 3
coronary artery 3
fat 2
body 2
HSD11B1 (Homo sapiens)
Pain Link Frequency Relevance Heat
rheumatoid arthritis 522 99.78 Very High Very High Very High
Analgesic 16 99.44 Very High Very High Very High
beta blocker 22 99.04 Very High Very High Very High
Clonidine 7 98.88 Very High Very High Very High
Restless leg syndrome 15 98.60 Very High Very High Very High
Angina 66 98.48 Very High Very High Very High
agonist 28 98.20 Very High Very High Very High
Pain 70 97.88 Very High Very High Very High
local anesthetic 5 97.84 Very High Very High Very High
Inflammation 270 97.20 Very High Very High Very High
Disease Link Frequency Relevance Heat
Disorder Of Lipid Metabolism 4038 100.00 Very High Very High Very High
Diabetes Mellitus 897 100.00 Very High Very High Very High
Metabolic Syndrome 408 100.00 Very High Very High Very High
Hypertension 260 100.00 Very High Very High Very High
Metabolic Disorder 13 100.00 Very High Very High Very High
Disease 492 99.92 Very High Very High Very High
Renal Disease 57 99.92 Very High Very High Very High
Weight Gain 18 99.90 Very High Very High Very High
Nicotine Addiction 240 99.88 Very High Very High Very High
Coronary Artery Disease 782 99.84 Very High Very High Very High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Rosuvastatin 10 mg increased HDL-C levels to a significantly greater extent than atorvastatin 20 mg (mean change 6.4% and 3.1%, p < 0.001), while similar reductions in TC, TG, and nonHDL-C levels were observed with both treatments (Table 2).
Negative_regulation (reductions) of HDL associated with disorder of lipid metabolism
1) Confidence 0.57 Published 2006 Journal Trials Section Body Doc Link PMC1779361 Disease Relevance 0.84 Pain Relevance 0
Because LCAT inhibition is followed by a decrease of HDL cholesterol and an increase of triglycerides in plasma, it is recommended to use only beta-blockers without such side effects on lipoprotein metabolism for therapeutical purposes.
Negative_regulation (decrease) of HDL in plasma associated with beta blocker and disorder of lipid metabolism
2) Confidence 0.57 Published 1984 Journal Int J Clin Pharmacol Ther Toxicol Section Abstract Doc Link 6548729 Disease Relevance 0.10 Pain Relevance 0.47
Ezetimibe therapy did reduce the LDL-C further, with an average reduction of 19.2%, with an accompanying reduction of HDL-C of 2.8 mg/dL (6.5%).
Negative_regulation (reduction) of HDL associated with disorder of lipid metabolism
3) Confidence 0.57 Published 2010 Journal Clinical Medicine Insights. Cardiology Section Body Doc Link PMC2978935 Disease Relevance 0.51 Pain Relevance 0
Furthermore, 12-week treatment with HCTZ resulted in significant increases in glucose (+11.0 +/- 4.1 mg/dl) and total cholesterol/HDL ratio (+0.3 +/- 0.1 mg/dl) and a significant decrease in HDL (-3.2 +/- 0.7 mg/dl).
Negative_regulation (decrease) of HDL associated with disorder of lipid metabolism
4) Confidence 0.57 Published 1998 Journal Cardiology Section Abstract Doc Link 9643274 Disease Relevance 0.59 Pain Relevance 0.07
High-density lipoprotein cholesterol and HDL/TC were significantly reduced in cigarette smokers, and HDL/TC was significantly reduced in men with myocardial infarction or angina pectoris and (albeit marginally) in diabetes mellitus as well.
Negative_regulation (reduced) of HDL associated with angina, nicotine addiction, diabetes mellitus, myocardial infarction and disorder of lipid metabolism
5) Confidence 0.57 Published 1986 Journal Prev Med Section Abstract Doc Link 3797389 Disease Relevance 2.37 Pain Relevance 0.10
HDL3 predominance in decreased HDL fraction and strongly decreased CE/TC ratio could be dependent of Apo C-I deficiency.
Negative_regulation (decreased) of HDL associated with disorder of lipid metabolism
6) Confidence 0.57 Published 1986 Journal Clin. Chim. Acta Section Abstract Doc Link 3731486 Disease Relevance 0.36 Pain Relevance 0.08
Nor do the centrally acting alpha-receptor agonists, such as methyldopa and clonidine have any unfavorable effect, with the exception of the decrease in the HDL cholesterol observed under methyldopa.
Negative_regulation (decrease) of HDL associated with agonist, disorder of lipid metabolism and clonidine
7) Confidence 0.57 Published 1993 Journal Fortschr. Med. Section Abstract Doc Link 8099558 Disease Relevance 0.27 Pain Relevance 0.18
Several beta-blockers given as monotherapy induce significant increases in Tg and a tendency for decreases in HDL-C.
Negative_regulation (decreases) of HDL associated with hypertriglyceridemia, beta blocker and disorder of lipid metabolism
8) Confidence 0.57 Published 1988 Journal Drugs Section Abstract Doc Link 3042351 Disease Relevance 0.63 Pain Relevance 0.16
RESULTS: (1) After 8 weeks of treatment, the serum level of triglyceride (TG) and high-density lipoprotein cholesterol (HDL-C) were reduced by 30% and 16% respectively in the niacin ER group compared with the baseline values (both P < 0.05).
Negative_regulation (reduced) of HDL
9) Confidence 0.57 Published 2006 Journal Zhonghua Yi Xue Za Zhi Section Body Doc Link 17156651 Disease Relevance 0.07 Pain Relevance 0
Age wise comparison revealed that level of total cholesterol; triglyceride and LDL-C were elevating while the level of HDL-C were decreasing with the age in cardiac and diabetic patients.
Negative_regulation (decreasing) of HDL associated with diabetes mellitus and disorder of lipid metabolism
10) Confidence 0.57 Published 2004 Journal Pak J Pharm Sci Section Abstract Doc Link 16414583 Disease Relevance 1.28 Pain Relevance 0.07
Another study showed only a significant reduction in HDL-C (p < 0.001) and apolipoproteina A1 (p = 0.004) in women assigned to exemestane with respect to the placebo group (Lonning et al 2005).
Negative_regulation (reduction) of HDL associated with disorder of lipid metabolism
11) Confidence 0.57 Published 2008 Journal Clinical Interventions in Aging Section Body Doc Link PMC2682397 Disease Relevance 0.99 Pain Relevance 0
The exemestane treated patients presented a significant (p < 0.01) decrease in HDL-C and TG and a significant increase in serum LDL-C, whereas the women who continued tamoxifen did not show any significant changes in lipid parameters (Montagnani et al 2007).
Negative_regulation (decrease) of HDL associated with hyperlipidemia and disorder of lipid metabolism
12) Confidence 0.57 Published 2008 Journal Clinical Interventions in Aging Section Body Doc Link PMC2682397 Disease Relevance 0.62 Pain Relevance 0
And, HDL-c (P < 0.001) was decreased with the increase of vessel score and Gensini's score.
Negative_regulation (decreased) of HDL associated with disorder of lipid metabolism
13) Confidence 0.57 Published 2009 Journal Lipids Health Dis Section Body Doc Link PMC2808301 Disease Relevance 0.81 Pain Relevance 0
The decrease in HDL-C per treatment was not significant.
Negative_regulation (decrease) of HDL associated with disorder of lipid metabolism
14) Confidence 0.57 Published 1992 Journal Clin Investig Section Abstract Doc Link 1600346 Disease Relevance 0.72 Pain Relevance 0.08
Beta-blocker monotherapy may often increase Tg and slightly decrease HDL-C.
Negative_regulation (decrease) of HDL associated with beta blocker and disorder of lipid metabolism
15) Confidence 0.57 Published 1983 Journal Hypertension Section Abstract Doc Link 6138309 Disease Relevance 0.32 Pain Relevance 0.28
HDL levels decreased in the control group from 60.20 ± 16.37 to 56.63 ± 12.67, and increased in the treatment group from 58.32 ± 11.64 to 59.74 ± 10.54.
Negative_regulation (decreased) of HDL associated with disorder of lipid metabolism
16) Confidence 0.50 Published 2007 Journal Yonsei Medical Journal Section Body Doc Link PMC2628120 Disease Relevance 0.51 Pain Relevance 0.03
Reductions in TC, TG, nonHDL-C, and ApoB levels were similar between treatments.
Negative_regulation (Reductions) of HDL associated with disorder of lipid metabolism
17) Confidence 0.42 Published 2006 Journal Trials Section Body Doc Link PMC1779361 Disease Relevance 1.65 Pain Relevance 0
Consistent with our results, Seki et al. [16] referred the decrease of serum total cholesterol level in quinazoline derivative-treated rats to reduction in serum VLDL-C and LDL-C rather than HDL-C levels.
Negative_regulation (reduction) of HDL associated with disorder of lipid metabolism
18) Confidence 0.42 Published 2005 Journal Lipids Health Dis Section Body Doc Link PMC1266394 Disease Relevance 0.80 Pain Relevance 0
The reduced atherogenic index in both treatments was mainly due to the decrease in serum total cholesterol level rather than elevation in serum HDL-C level.


Negative_regulation (decrease) of HDL associated with disorder of lipid metabolism
19) Confidence 0.42 Published 2005 Journal Lipids Health Dis Section Body Doc Link PMC1266394 Disease Relevance 0.87 Pain Relevance 0
Lower HDL-C levels are associated with worse ABI and decreased peak oxygen uptake in postmenopausal women with PAD.
Negative_regulation (decreased) of HDL associated with peripheral arterial disease and disorder of lipid metabolism
20) Confidence 0.42 Published 2010 Journal Angiology Section Abstract Doc Link 20529977 Disease Relevance 1.02 Pain Relevance 0.22

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox